- Company
- 'Leclaza·Rybrevant comb therapy' wins nod in KOR
- by Son, Hyung Min Jan 14, 2025 05:56am
- The approval of Leclaza plus Rybrevant combination therapy in South Korea has expanded treatment options for patients with non-small cell lung cancer (NSCLC). As Leclaza combination therapy has shown a positive overall survival (OS) result, it is highly likely to be the first-line standard therapy for treating EGFR-positive NSCLC. Accordin
- Company
- Samsung Bioepis partners with Teva for Soliris biosimilar
- by Cha, Jihyun Jan 14, 2025 05:56am
- Samsung Bioepis announced on the 12th that it has signed a commercialization partnership agreement with the multinational pharmaceutical company Teva Pharmaceutical Industries to launch Epysqli, a biosimilar of the rare disease treatment Soliris (eculizumab), in the U.S. market. Epysqli is the first hematology biosimilar developed by Sam
- Company
- Will biotech companies continue 'K-Bio' success?
- by Moon, sung-ho Jan 13, 2025 05:53am
- Korean pharmaceutical and biotech companies have successfully outlicensed new drugs in various fields, including cancer, autoimmune disease, and Alzheimer's disease. However, compared to the year before, analysis suggests that the number of out-licensed cases decreased. Despite such a slowdown, companies focusing on global new drug developmen
- Company
- Samsung Bioepis to indirectly sell Soliris biosimilar in US
- by Cha, Jihyun Jan 13, 2025 05:53am
- Samsung Bioepis has signed a partnership agreement with the multinational pharmaceutical company Teva Pharmaceuticals to commercialize biosimilars of rare disease treatments in the United States. Samsung Bioepis will launch the biosimilar through Teva in the U.S. market in the first half of this year. Unlike in Europe, where Samsung Bioepis h
- Company
- Wegovy can be prescribed in tertiary hospitals in KOR
- by Eo, Yun-Ho Jan 13, 2025 05:53am
- The obesity drug ‘Wegovy’ can now be prescribed in tertiary hospitals in Korea. According to industry sources, Novo Nordisk Korea's Wegovy (semaglutide) has passed the drug committees (DCs) of Korrea’s “Big 5 medical institutions,” including Samsung Medical Center, Seoul National University Hospital, and Sinchon Severance Hospital.
- Policy
- Will 'Lorviqua' secure a deal on drug price negotiations?
- by Lee, Tak-Sun Jan 13, 2025 05:53am
- The reimbursement expansion case for Lorviqua (lorlatinib, Pfizer), which was stalled during the drug price negotiation last year, has passed the Drug Reimbursement Evaluation Committee (DREC) of the Health Insurance Review and Assessment Service (HIRA) under a conditional term. It draws attention to whether it will succeed this round. Pfi
- Policy
- New criteria set for unstable supply and demand drugs
- by Lee, Tak-Sun Jan 13, 2025 05:53am
- The Health Insurance Review and Assessment Service has decided to clarify the criteria for evaluating adjustment applications for drugs with unstable supply and demand and strengthen preliminary management of high-priced anticancer drugs. HIRA announced so on the 9th while issuing a prenotification of the “Partial Amendments to the Eva
- Company
- Imported API from China·India reaches 50%
- by Kim, Jin-Gu Jan 13, 2025 05:53am
- It has been reported that half of the active ingredients (API) imported to South Korea are produced in China and India. The percentage of imported active ingredients originating from China·India surpassed 50% in two consecutive years. The percentage of imported API from India has robustly increased recently. Indian API imports were below 10
- Company
- Sanofi’s Hexaxim is included in NIP from this year
- by Whang, byung-woo Jan 10, 2025 05:52am
- Sanofi announced on the 9th that Hexaxim, its hexavalent combination vaccine for infants, has been included in Korea’s National Immunization Program (NIP). With its introduction to the NIP, Hexaxim can now be administered free of charge at designated medical institutions under the National Immunization Program for Children. As the fir
- Policy
- Chinese pharma targeting KOR, BeiGene gets greenlight
- by Lee, Hye-Kyung Jan 10, 2025 05:52am
- BeiGene Korea expands market dominance by conducting clinical trials to achieve competitiveness in the Korean market. Based on this year's Ministry of Food and Drug Safety (MFDS)'s clinical trial approval report, two out of ten approved clinical trial applications were BeiGene Korea's Phase 1 clinical trials. BeiGene has been strengthen
